TXNRD2 and prostate cancer: Moreover, a previous study demonstrated that targeting mitochondrial antioxidants, including manganese superoxide dismutase (MnSOD), glutathione peroxidase 2 (Gpx2), and thioredoxin reductase 2 (TrxR2) by microRNA-17-3p remarkably sensitized prostate cancer cells to IR.